Literature DB >> 3067984

Surgery and current management for cancer of the esophagus and cardia.

T R DeMeester1, A P Barlow.   

Abstract

The current status of carcinoma of the esophagus is reviewed, with specific discussions on current problems. These are difficulties in staging the disease, confusion in the classification, surgery vs. radiation therapy, palliative vs. curative resection, transthoracic vs. transhiatal resection for palliation, and stomach vs. colon as an esophageal substitute after resection. The importance of dysphagia as the presenting complaint is stressed, and the etiologic factors for squamous and adenocarcinoma are reviewed, with a focus on Barrett's esophagus. In management, an emphasis is placed on intraoperative staging, the selection of patients for curative resection, the theory and use of en bloc resection, and the effect of tumor localization on the choice of surgical procedure. A description of the operative technique for cervical lesions, and transthoracic, transhiatal, and en bloc resection of thoracic lesions is given. The palliative benefit of bougienage, intubation, surgical bypass, radiotherapy, laser therapy, and electrical coagulation is summarized. The benefits of intubation are stressed. The recent advent of combination therapy, particularly with regard to chemotherapy and surgery, is discussed. Although such therapy is exciting in isolated patients, the results are not sufficiently predictable to be considered as standard therapy. More work needs to be done to identify those patients most apt to benefit from the variety of therapeutic modalities available.

Entities:  

Mesh:

Year:  1988        PMID: 3067984     DOI: 10.1016/s0147-0272(88)80002-3

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN: 0147-0272            Impact factor:   3.187


  2 in total

Review 1.  Society for Translational Medicine Expert Consensus on the prevention and treatment of postoperative pulmonary infection in esophageal cancer patients.

Authors:  Zhentao Yu; Shanqing Li; Deruo Liu; Lunxu Liu; Jianxing He; Yunchao Huang; Shidong Xu; Weimin Mao; Qunyou Tan; Chun Chen; Xiaofei Li; Zhu Zhang; Gening Jiang; Lin Xu; Lanjun Zhang; Jianhua Fu; Hui Li; Qun Wang; Lijie Tan; Danqing Li; Qinghua Zhou; Xiangning Fu; Zhongmin Jiang; Haiquan Chen; Wentao Fang; Xun Zhang; Yin Li; Ti Tong; Yongyu Liu; Xiuyi Zhi; Tiansheng Yan; Xingyi Zhang; Lei Gong; Hongdian Zhang; John B Downs; Nestor Villamizar; Shugeng Gao; Jie He
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

2.  Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma.

Authors:  Elisabeth I Heath; Barbara A Burtness; Lawrence Kleinberg; Ronald R Salem; Stephen C Yang; Richard F Heitmiller; Marcia I Canto; Jonathan P S Knisely; Mark Topazian; Elizabeth Montgomery; Nancy Tsottles; Yazdi Pithavala; Bridget Rohmiller; Mary Collier; Arlene A Forastiere
Journal:  Invest New Drugs       Date:  2006-03       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.